Evidence map›Paper›PMID 28765558›Full record

ArticleScientific reports2017

Cardiac spheroids as promising in vitro models to study the human heart microenvironment.

Liudmila Polonchuk, Mamta Chabria, Laura Badi, Jean-Christophe Hoflack, Gemma Figtree, Michael J Davies, Carmine Gentile

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 219 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Stimuli-responsive hybrid materials for 4DMaterials today. Bio · 2025
    Review
  17. Generation and applications of cardiac spheroids.npj biomedical innovations · 2025
    Review
  18. Review
  19. Key parameters for designing robust 2D and 3D spheroid models forBioengineering & translational medicine · 2025
    Review
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 4 countries.

Liudmila PolonchukRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, 4070, Switzerland.ORCID 0000-0002-6947-2845
Mamta ChabriaRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, 4070, Switzerland.
Laura BadiRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, 4070, Switzerland.
Jean-Christophe HoflackRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, 4070, Switzerland.
Gemma FigtreeSydney Medical School, University of Sydney, Sydney, 2000, Australia.
Michael J DaviesDepartment of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, 2200, Denmark.ORCID 0000-0002-5196-6919
Carmine GentileSydney Medical School, University of Sydney, Sydney, 2000, Australia. carmine.gentile@sydney.edu.au.
Roche (Switzerland) · CHThe University of Sydney · AUUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three-dimensional in vitro cell systems are a promising alternative to animals to study cardiac biology and disease. We have generated three-dimensional in vitro models of the human heart ("cardiac spheroids", CSs) by co-culturing human primary or iPSC-derived cardiomyocytes, endothelial cells and fibroblasts at ratios approximating those present in vivo. The cellular organisation, extracellular matrix and microvascular network mimic human heart tissue. These spheroids have been employed to investigate the dose-limiting cardiotoxicity of the common anti-cancer drug doxorubicin. Viability/cytotoxicity assays indicate dose-dependent cytotoxic effects, which are inhibited by the nitric oxide synthase (NOS) inhibitor L-NIO, and genetic inhibition of endothelial NOS, implicating peroxynitrous acid as a key damaging agent. These data indicate that CSs mimic important features of human heart morphology, biochemistry and pharmacology in vitro, offering a promising alternative to animals and standard cell cultures with regard to mechanistic insights and prediction of toxic effects in human heart tissue.

Indexed as

Antineoplastic AgentsCell SurvivalDoxorubicinEndothelial CellsFibroblastsHeartHumansModels, BiologicalMyocytes, CardiacSpheroids, CellularAntineoplastic AgentsDoxorubicin

Identifiers

PMID28765558
PMCPMC5539326
OpenAlexW2737012672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.